Real-word experience with Mepolizumab: Does it deliver what it has promised?,Clinical & Experimental Allergy

当前位置： X-MOL 学术 › Clin. Exp. Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Real-word experience with Mepolizumab: Does it deliver what it has promised?
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2020-04-14 , DOI: 10.1111/cea.13601
Florence Schleich _{1,

2} , Sophie Graff _{1,

2} , Haleh Nekoee ₃ , Catherine Moermans _{1,

2} , Monique Henket _{1,

2} , Carole Sanchez _{1,

2} , Virginie Paulus _{1,

2} , Françoise Guissard _{1,

2} , Anne-Françoise Donneau ₃ , Renaud Louis _{1,

2}

Affiliation

Randomized control trials performed in selected populations of severe eosinophilic asthmatics have shown that mepolizumab, an anti‐IL5 therapy, was able to reduce exacerbations and OCS maintenance dose and in some studies, to improve asthma control and lung function.

中文翻译：